Form 4: Schrodinger Executive Acquires 60,000 Stock Options

Yvonne Tran, EVP, CLO & CPO of Schrodinger, Inc., reports the acquisition of 60,000 stock options on March 4, 2024.

Summary

• Yvonne Tran, an executive at Schrodinger, Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 60,000 stock options on March 4, 2024, at an exercise price of $25.24.
• These options vest over a four-year period, starting with 25% on March 4, 2025, and the remainder in equal monthly installments through March 4, 2028.
• Following the transaction, Ms. Tran directly owns 60,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine executive compensation disclosure. The grant itself is a positive incentive for the executive, but the filing is simply a required disclosure.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the technology and pharmaceutical industries, often used to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the tech and biotech sectors.
• The vesting schedule of 25% after one year followed by monthly installments is a typical vesting structure.
• Comparing the size of this grant to similar grants at comparable companies like Relay Therapeutics or Recursion Pharmaceuticals would provide further context.

Stakeholder Impact

• The stock option grant could potentially incentivize the executive to improve company performance, benefiting shareholders.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates